| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
|
N Engl J Med
|
2004
|
30.26
|
|
2
|
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
|
Lancet
|
2010
|
25.32
|
|
3
|
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
20.89
|
|
4
|
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
|
N Engl J Med
|
2013
|
16.24
|
|
5
|
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
Lancet Oncol
|
2010
|
13.25
|
|
6
|
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
12.00
|
|
7
|
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
|
N Engl J Med
|
2011
|
11.93
|
|
8
|
Everolimus for advanced pancreatic neuroendocrine tumors.
|
N Engl J Med
|
2011
|
11.55
|
|
9
|
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
|
Lancet
|
2008
|
9.92
|
|
10
|
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
JAMA
|
2010
|
8.21
|
|
11
|
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
|
J Clin Oncol
|
2004
|
7.16
|
|
12
|
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
|
J Clin Oncol
|
2009
|
7.04
|
|
13
|
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
|
J Clin Oncol
|
2011
|
6.18
|
|
14
|
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
5.86
|
|
15
|
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
5.62
|
|
16
|
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
|
JAMA
|
2010
|
5.04
|
|
17
|
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
|
Lancet
|
2011
|
4.79
|
|
18
|
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
|
J Clin Oncol
|
2011
|
3.99
|
|
19
|
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
|
J Clin Oncol
|
2007
|
3.51
|
|
20
|
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
|
J Clin Oncol
|
2008
|
3.49
|
|
21
|
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
|
Lancet Oncol
|
2011
|
3.44
|
|
22
|
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
|
J Clin Oncol
|
2009
|
3.18
|
|
23
|
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2004
|
3.10
|
|
24
|
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
|
N Engl J Med
|
2015
|
3.09
|
|
25
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2012
|
3.02
|
|
26
|
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
|
Lancet Oncol
|
2013
|
2.94
|
|
27
|
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
|
J Clin Oncol
|
2009
|
2.92
|
|
28
|
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
|
Lancet Oncol
|
2012
|
2.92
|
|
29
|
Gastric cancer.
|
Crit Rev Oncol Hematol
|
2009
|
2.87
|
|
30
|
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
J Clin Oncol
|
2012
|
2.86
|
|
31
|
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
|
Eur J Cancer
|
2012
|
2.79
|
|
32
|
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
|
J Clin Oncol
|
2011
|
2.76
|
|
33
|
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
|
J Clin Oncol
|
2012
|
2.66
|
|
34
|
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
|
J Clin Oncol
|
2010
|
2.66
|
|
35
|
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
|
J Clin Oncol
|
2011
|
2.57
|
|
36
|
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
|
J Clin Oncol
|
2005
|
2.52
|
|
37
|
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
|
J Natl Cancer Inst
|
2012
|
2.49
|
|
38
|
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
|
Nat Rev Clin Oncol
|
2009
|
2.48
|
|
39
|
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
|
J Clin Oncol
|
2006
|
2.48
|
|
40
|
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
|
J Clin Oncol
|
2007
|
2.47
|
|
41
|
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).
|
Ann Surg
|
2012
|
2.43
|
|
42
|
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
|
Lancet Oncol
|
2009
|
2.41
|
|
43
|
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
|
J Clin Oncol
|
2007
|
2.36
|
|
44
|
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
|
Clin Cancer Res
|
2009
|
2.25
|
|
45
|
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
|
J Clin Oncol
|
2010
|
2.19
|
|
46
|
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
|
Neuroendocrinology
|
2004
|
2.16
|
|
47
|
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
|
J Clin Oncol
|
2013
|
2.14
|
|
48
|
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
|
Lancet Oncol
|
2007
|
2.14
|
|
49
|
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
|
J Clin Oncol
|
2013
|
2.14
|
|
50
|
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
|
J Clin Oncol
|
2012
|
2.07
|
|
51
|
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors.
|
Surg Endosc
|
2012
|
2.04
|
|
52
|
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
Clin Cancer Res
|
2013
|
2.03
|
|
53
|
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
|
J Clin Oncol
|
2008
|
1.97
|
|
54
|
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
J Clin Oncol
|
2012
|
1.97
|
|
55
|
Potential regional differences for the tolerability profiles of fluoropyrimidines.
|
J Clin Oncol
|
2008
|
1.92
|
|
56
|
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
|
Oncologist
|
2007
|
1.89
|
|
57
|
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
|
J Clin Oncol
|
2009
|
1.87
|
|
58
|
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
|
Clin Cancer Res
|
2008
|
1.80
|
|
59
|
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
|
J Clin Oncol
|
2007
|
1.79
|
|
60
|
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
|
Oncologist
|
2012
|
1.76
|
|
61
|
European experts consensus statement on cystic tumours of the pancreas.
|
Dig Liver Dis
|
2013
|
1.75
|
|
62
|
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
|
Oncologist
|
2010
|
1.72
|
|
63
|
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
|
J Clin Oncol
|
2010
|
1.65
|
|
64
|
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
|
J Clin Oncol
|
2007
|
1.63
|
|
65
|
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
|
J Clin Oncol
|
2013
|
1.62
|
|
66
|
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
|
J Clin Oncol
|
2010
|
1.61
|
|
67
|
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
|
Eur J Cancer
|
2007
|
1.58
|
|
68
|
Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
|
Clin Cancer Res
|
2014
|
1.55
|
|
69
|
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).
|
Radiother Oncol
|
2009
|
1.55
|
|
70
|
Gastric electrical stimulation in intractable symptomatic gastroparesis.
|
Digestion
|
2002
|
1.51
|
|
71
|
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
|
J Clin Oncol
|
2010
|
1.49
|
|
72
|
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
|
Clin Cancer Res
|
2005
|
1.45
|
|
73
|
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
|
Invest New Drugs
|
2008
|
1.36
|
|
74
|
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
|
J Clin Oncol
|
2006
|
1.34
|
|
75
|
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.
|
Target Oncol
|
2011
|
1.32
|
|
76
|
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
|
Cancer
|
2009
|
1.31
|
|
77
|
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
|
J Dtsch Dermatol Ges
|
2005
|
1.31
|
|
78
|
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
|
J Natl Cancer Inst
|
2013
|
1.28
|
|
79
|
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
|
Eur J Cancer
|
2012
|
1.27
|
|
80
|
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
|
Ann Surg Oncol
|
2012
|
1.25
|
|
81
|
Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
|
J Clin Oncol
|
2010
|
1.24
|
|
82
|
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
|
Mol Cancer Ther
|
2006
|
1.24
|
|
83
|
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
|
Cancer Lett
|
2012
|
1.24
|
|
84
|
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
|
Eur J Cancer
|
2013
|
1.24
|
|
85
|
Role of targeted agents in metastatic colorectal cancer.
|
Target Oncol
|
2013
|
1.22
|
|
86
|
Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.
|
Nat Rev Gastroenterol Hepatol
|
2010
|
1.21
|
|
87
|
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
|
Eur J Cancer
|
2005
|
1.20
|
|
88
|
New strategies for treatment of KRAS mutant metastatic colorectal cancer.
|
Clin Cancer Res
|
2010
|
1.19
|
|
89
|
Gastric cancer.
|
Crit Rev Oncol Hematol
|
2005
|
1.16
|
|
90
|
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
|
J Clin Oncol
|
2013
|
1.12
|
|
91
|
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
|
J Support Oncol
|
2008
|
1.11
|
|
92
|
Management of advanced gastric cancer.
|
Expert Rev Gastroenterol Hepatol
|
2012
|
1.09
|
|
93
|
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.
|
Eur J Cancer
|
2007
|
1.07
|
|
94
|
Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.07
|
|
95
|
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
|
Oncology
|
2005
|
1.06
|
|
96
|
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
|
Clin Cancer Res
|
2013
|
1.03
|
|
97
|
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
|
Invest New Drugs
|
2014
|
1.03
|
|
98
|
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
|
Ann Surg Oncol
|
2010
|
0.99
|
|
99
|
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
|
Clin Cancer Res
|
2009
|
0.97
|
|
100
|
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer.
|
Ann Surg Oncol
|
2012
|
0.97
|
|
101
|
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
|
Eur J Cancer
|
2012
|
0.96
|
|
102
|
Acute and long-term gastrointestinal consequences of chemotherapy.
|
Best Pract Res Clin Gastroenterol
|
2009
|
0.96
|
|
103
|
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
|
Angiogenesis
|
2014
|
0.94
|
|
104
|
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
|
Radiother Oncol
|
2004
|
0.94
|
|
105
|
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
|
Oncology (Williston Park)
|
2007
|
0.93
|
|
106
|
Skin toxicities of targeted therapies.
|
Eur J Cancer
|
2009
|
0.93
|
|
107
|
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus.
|
Radiother Oncol
|
2005
|
0.92
|
|
108
|
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
|
Ann Surg Oncol
|
2012
|
0.91
|
|
109
|
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer.
|
Eur J Cancer
|
2008
|
0.91
|
|
110
|
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
|
Eur J Cancer
|
2013
|
0.90
|
|
111
|
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.
|
Target Oncol
|
2013
|
0.90
|
|
112
|
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
|
JAMA
|
2005
|
0.89
|
|
113
|
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.
|
J Clin Oncol
|
2013
|
0.89
|
|
114
|
Clinical research of EGFR inhibitors and related dermatologic toxicities.
|
Oncology (Williston Park)
|
2007
|
0.88
|
|
115
|
Stool tagging applied in thin-slice multidetector computed tomography colonography.
|
J Comput Assist Tomogr
|
2003
|
0.88
|
|
116
|
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
|
J Clin Oncol
|
2005
|
0.87
|
|
117
|
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
|
PLoS One
|
2013
|
0.87
|
|
118
|
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
|
Neuroendocrinology
|
2015
|
0.86
|
|
119
|
Lessons learned in the management of advanced pancreatic cancer.
|
J Clin Oncol
|
2007
|
0.86
|
|
120
|
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
|
Pancreas
|
2015
|
0.85
|
|
121
|
What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation?
|
Cancer Treat Rev
|
2013
|
0.85
|
|
122
|
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
|
Cancer Chemother Pharmacol
|
2009
|
0.85
|
|
123
|
A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma.
|
Clin Cancer Res
|
2010
|
0.84
|
|
124
|
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
|
Eur J Oncol Nurs
|
2004
|
0.84
|
|
125
|
Prospective comparison of hydrogel-coated microcoils versus fibered platinum microcoils in the prophylactic embolization of the gastroduodenal artery before yttrium-90 radioembolization.
|
J Vasc Interv Radiol
|
2013
|
0.83
|
|
126
|
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.
|
J Surg Oncol
|
2010
|
0.82
|
|
127
|
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.
|
Target Oncol
|
2011
|
0.82
|
|
128
|
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
|
Clin Colorectal Cancer
|
2013
|
0.82
|
|
129
|
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.82
|
|
130
|
The timing of chemotherapy and surgery for the treatment of colorectal liver metastases.
|
Clin Colorectal Cancer
|
2010
|
0.82
|
|
131
|
Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature.
|
Acta Gastroenterol Belg
|
2007
|
0.81
|
|
132
|
Molecular and genetic defects in colorectal tumorigenesis.
|
Best Pract Res Clin Gastroenterol
|
2002
|
0.81
|
|
133
|
Different surgical strategies in the treatment of familial adenomatous polyposis: what's the role of the ileorectal anastomosis?
|
Acta Gastroenterol Belg
|
2011
|
0.81
|
|
134
|
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.
|
Onco Targets Ther
|
2013
|
0.81
|
|
135
|
Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planning.
|
Clin Nucl Med
|
2013
|
0.81
|
|
136
|
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.
|
BMC Cancer
|
2007
|
0.81
|
|
137
|
Impact of molecular markers on treatment selection in advanced colorectal cancer.
|
Eur J Cancer
|
2009
|
0.81
|
|
138
|
Perineal colostomy with appendicostomy as an alternative for an abdominal colostomy: symptoms, functional status, quality of life, and perceived health.
|
Dis Colon Rectum
|
2007
|
0.80
|
|
139
|
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
|
Radiother Oncol
|
2009
|
0.80
|
|
140
|
The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP).
|
Acta Gastroenterol Belg
|
2011
|
0.80
|
|
141
|
Computed tomographic colonography: automated tool for polyp measurement delivering on patient risk stratification.
|
J Comput Assist Tomogr
|
2008
|
0.79
|
|
142
|
Regorafenib for metastatic colorectal cancer - Authors' reply.
|
Lancet
|
2013
|
0.79
|
|
143
|
Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.
|
Eur Radiol
|
2010
|
0.79
|
|
144
|
Significant impact of transient deterioration of renal function on dosimetry in PRRT.
|
Ann Nucl Med
|
2012
|
0.79
|
|
145
|
Oncological management of unresectable liver metastases.
|
Dig Dis
|
2012
|
0.79
|
|
146
|
Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD).
|
Eur J Hum Genet
|
2002
|
0.78
|
|
147
|
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
|
Clin Colorectal Cancer
|
2013
|
0.78
|
|
148
|
Genetic markers of bevacizumab-induced hypertension.
|
Angiogenesis
|
2014
|
0.78
|
|
149
|
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
|
Radiat Oncol
|
2008
|
0.77
|
|
150
|
Clinical management of EGFRI dermatologic toxicities: the European perspective.
|
Oncology (Williston Park)
|
2007
|
0.76
|
|
151
|
Progress with biological agents in metastatic colorectal cancer leads to many challenges.
|
J Clin Oncol
|
2006
|
0.76
|
|
152
|
Improved first-line chemotherapy: a better chance for surgery?
|
Lancet Oncol
|
2009
|
0.75
|
|
153
|
T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status.
|
World J Gastrointest Oncol
|
2011
|
0.75
|
|
154
|
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
|
J Clin Oncol
|
2008
|
0.75
|
|
155
|
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
|
J Clin Oncol
|
2011
|
0.75
|
|
156
|
Treatment-related mortality with aflibercept in cancer patients.
|
Eur J Clin Pharmacol
|
2014
|
0.75
|
|
157
|
The search for optimal response prediction in cancer leads to a personalized approach.
|
Target Oncol
|
2010
|
0.75
|
|
158
|
European initiatives in colorectal cancer screening.
|
Eur J Gastroenterol Hepatol
|
2011
|
0.75
|
|
159
|
Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
|
Nuklearmedizin
|
2016
|
0.75
|
|
160
|
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
|
Curr Opin Mol Ther
|
2010
|
0.75
|